JP2023551027A5 - - Google Patents

Info

Publication number
JP2023551027A5
JP2023551027A5 JP2023532547A JP2023532547A JP2023551027A5 JP 2023551027 A5 JP2023551027 A5 JP 2023551027A5 JP 2023532547 A JP2023532547 A JP 2023532547A JP 2023532547 A JP2023532547 A JP 2023532547A JP 2023551027 A5 JP2023551027 A5 JP 2023551027A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
sequence shown
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551027A (ja
Filing date
Publication date
Priority claimed from CN202011332200.9A external-priority patent/CN112480248B/zh
Application filed filed Critical
Publication of JP2023551027A publication Critical patent/JP2023551027A/ja
Publication of JP2023551027A5 publication Critical patent/JP2023551027A5/ja
Pending legal-status Critical Current

Links

JP2023532547A 2020-11-24 2021-11-23 Ｃｌｄｎ１８．２に特異的に結合する分子 Pending JP2023551027A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011332200.9A CN112480248B (zh) 2020-11-24 2020-11-24 与cld18a2特异性结合的分子
CN202011332200.9 2020-11-24
PCT/CN2021/132218 WO2022111425A1 (zh) 2020-11-24 2021-11-23 与cldn18.2特异性结合的分子

Publications (2)

Publication Number Publication Date
JP2023551027A JP2023551027A (ja) 2023-12-06
JP2023551027A5 true JP2023551027A5 (enExample) 2024-01-11

Family

ID=74934321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532547A Pending JP2023551027A (ja) 2020-11-24 2021-11-23 Ｃｌｄｎ１８．２に特異的に結合する分子

Country Status (7)

Country Link
US (1) US20240092891A1 (enExample)
EP (1) EP4253411A4 (enExample)
JP (1) JP2023551027A (enExample)
CN (2) CN112480248B (enExample)
AU (1) AU2021387558A1 (enExample)
CA (1) CA3200052A1 (enExample)
WO (1) WO2022111425A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
EP4347663A4 (en) * 2021-05-31 2025-05-14 Shijiazhuang Yiling Pharmaceutical Co., Ltd. MONOCLONAL ANTIBODIES AGAINST CLDN18.2 AND THEIR FC-MODIFIED VERSIONS
CN115611983A (zh) * 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
KR20240044467A (ko) * 2021-08-09 2024-04-04 하버 바이오메드 (상하이) 컴퍼니 리미티드 Cldn18.2-표적화 항체, 이중특이적 항체, 및 이들의 용도
WO2023025306A1 (zh) * 2021-08-27 2023-03-02 三优生物医药(上海)有限公司 靶向pd-l1和cldn18.2的双特异性抗体及其制备方法和应用
CN115991784A (zh) 2021-10-19 2023-04-21 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体及其用途
WO2023078386A1 (zh) * 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
CN120379697A (zh) * 2022-12-26 2025-07-25 辐联科技香港有限公司 缀合物及其用途
EP4719486A1 (en) * 2023-05-31 2026-04-08 Full-Life Technologies UK Limited Conjugates and uses thereof
CN117327182B (zh) * 2023-09-19 2024-06-04 上海交通大学医学院附属仁济医院 Cldn18.2单域抗体探针的制备方法及应用
CN117304323A (zh) * 2023-09-28 2023-12-29 南京蓬勃生物科技有限公司 结合Claudin 18.2的结合部分及其应用
WO2026076388A1 (en) * 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH591382A5 (enExample) 1974-05-28 1977-09-15 Ferag Ag
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CA2815888C (en) * 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
DK3254695T3 (da) * 2012-05-23 2020-11-30 Astellas Pharma Inc Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
CN116178554B (zh) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
CN111848809A (zh) * 2019-04-08 2020-10-30 上海健信生物医药科技有限公司 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途
CN111518214B (zh) * 2019-02-03 2023-09-22 上海健信生物医药科技有限公司 靶向cldn18.2的双特异性抗体及其制备方法和应用
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
BR112021002032A2 (pt) * 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
CN114106183B (zh) * 2019-01-15 2023-06-23 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CA3141504A1 (en) * 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途
CN111961135B (zh) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 一种用于预防或治疗癌症的抗体
US20220112276A1 (en) * 2020-10-12 2022-04-14 Janssen Biotech, Inc. Biosynthetic materials and methods for multidirectional biotransportation
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子

Similar Documents

Publication Publication Date Title
Könning et al. Camelid and shark single domain antibodies: structural features and therapeutic potential
Safdari et al. Antibody humanization methods–a review and update
JP2023539245A5 (enExample)
CN100415765C (zh) 兔单克隆抗体的人源化方法
EP3183272B1 (en) Asymmetric multispecific antibodies
JP2020525032A5 (enExample)
JP2020508655A5 (enExample)
JP2012501670A5 (enExample)
JP2019527553A5 (enExample)
JP2020031650A (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
CN119684457A (zh) 针对c-kit的人源化抗体
JP2018522888A5 (enExample)
JP2012501669A5 (enExample)
JP2021520832A5 (enExample)
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
JP2018526981A5 (enExample)
WO2013064701A2 (en) Bispecific antibodies and methods for isolating same
HRP20191697T1 (hr) Vezujuće molekule za bcma i cd3
RU2021111382A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2021530244A5 (enExample)
JP2023543493A5 (enExample)
JP2023511898A5 (enExample)
CN109721656B (zh) 靶向rankl的治疗性抗体
JP2023537958A5 (enExample)
JP2024516098A5 (enExample)